Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for researchers · Friday, March 1, 2024 · 692,472,519 Articles · 3+ Million Readers

Respiratory Diagnostics Market worth $10.96 billion by 2030- Exclusive Report by 360iResearch

Respiratory Diagnostics Market - Exclusive Report by 360iResearch

The Global Respiratory Diagnostics Market to grow from USD 5.62 billion in 2022 to USD 10.96 billion by 2030, at a CAGR of 8.70%.

PUNE, MAHARASHTRA, INDIA , December 6, 2023 / -- The "Respiratory Diagnostics Market by Product (Assays & Reagents, Instruments & Devices, Software & Services), Test Type (Imaging Tests, Mechanical Tests, Molecular Diagnostic Tests), Indication, End-User - Global Forecast 2023-2030" report has been added to's offering.

The Global Respiratory Diagnostics Market to grow from USD 5.62 billion in 2022 to USD 10.96 billion by 2030, at a CAGR of 8.70%.

Request a Free Sample Report @

Respiratory diagnostics is a vital component of the healthcare industry, focusing on the identification, monitoring, and treatment of respiratory diseases, which include asthma, chronic obstructive pulmonary disease (COPD), lung tumors, tuberculosis, and pneumonia, among others. Respiratory diagnostics testing methods encompass the use of imaging tests, spirometry, peak flow tests, blood gas tests, pulmonary function tests, and multiple other diagnostic techniques. Escalation in the prevalence of such respiratory conditions due to rising air pollution levels, smoking, genetic predispositions, and occupational hazards has necessitated the use of respiratory diagnostics solutions. However, inadequate reimbursement and insurance policies and the risk of errors associated with complex diagnostic procedures could also impede the proliferation of respiratory diagnostics. Moreover, the need for trained professionals to operate advanced diagnostic systems presents a challenge to the market's expansion. However, government initiatives aimed at enhancing health infrastructure and access to respiratory health solutions and increasing investments in research and development activities can help overcome the financial and technical limitations of respiratory diagnostics solutions. Innovations such as portable monitoring devices, advanced molecular diagnostic tests, and increased digitalization leading to the incorporation of telehealth services in respiratory care offer new areas for growth.

Indication: Need for advanced respiratory diagnostic technologies to attain accurate testing of chronic obstructive pulmonary disease
Asthma is a chronic condition characterized by difficulty in breathing due to frequent, underlying inflammation of the airways. Respiratory diagnostic strategies for asthma usually involve pulmonary function tests, such as spirometry, which assess the extent of airway obstruction and reversibility. Moreover, the measurement of fractional exhaled nitric oxide (FeNO) indirectly reflects airway inflammation, providing further diagnostic insight. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that causes breathing difficulties and features chronic bronchitis and emphysema. Respiratory diagnostics for COPD involve a range of tests, including the spirometry test to measure lung function, a chest X-ray or CT scan to view the lungs, and arterial blood gas analysis to measure how well the lungs are transferring oxygen to the bloodstream and removing carbon dioxide. Lung cancer, a serious and potentially fatal disease, often originates in the cells lining the bronchi or bronchioles. Diagnosis typically includes imaging tests such as chest X-rays and CT scans for initial detection. Pneumonia is an infection that inflames the air sacs in one or both lungs. The disease is typically diagnosed through physical examinations, followed by a chest X-ray, which can confirm the infection and determine its location and extent. Additionally, sputum tests and blood tests can be utilized to identify the type of microorganism causing the infection, helping to determine the most effective treatment approach. Tuberculosis is a potentially severe infectious disease affecting primarily the lungs. Two main tests are used in respiratory diagnostics for TB: the skin test, which identifies TB exposure, and the interferon-gamma release assay, which can confirm active or latent infection. A chest X-ray or CT scan may be used to assess lung damage further, while a sputum test can reveal if the strain of TB is drug-resistant, assisting in treatment planning.

Test Type: Research initiatives to advance the accuracy and specificity of molecular diagnostic tests
Imaging tests play a critical role in visualizing the structure of the respiratory system, aiding in the diagnosis of abnormalities, and monitoring disease progression. Imaging tests such as computed tomography (CT) provide a more detailed cross-sectional view of the lungs, highlighting nodules, tumors, and complex lung diseases, while magnetic resonance imaging (MRI) is useful in detailed imaging of the chest wall, mediastinum, and occasionally soft tissue abnormalities. Mechanical tests evaluate the physical function of the lungs. Pulmonary function tests (PFTs) measure lung volume, capacity, rates of flow, and gas exchange, while spirometry assesses how well the lungs function by measuring the speed and volume of air that can be inhaled or exhaled. Molecular diagnostics involve analyzing biomarkers at the molecular level, providing information on genetic predispositions, infectious pathogens, and specific characteristics of diseases, enabling precision medicine. Polymerase chain reaction (PCR) is used to detect the presence of bacterial and viral pathogens or infections in respiratory illnesses. Obstructive sleep apnea (OSA) tests are vital in assessing periods of shallow or paused breathing during sleep. Traditional respiratory diagnostics involve basic laboratory tests, such as microscopy and biochemical tests. For tuberculosis case detection, microscopy continues to be an indispensable diagnostics tool, given its low cost, rapidity, simplicity of procedure, and high specificity.

Product: Need for rapid detection of pathogens driving the adoption of assays and reagents
Respiratory diagnostic instruments and devices are specifically designed to perform various tests that help identify lung and respiratory disorders. These include spirometers, nebulizers, peak flow meters, oscillometers, polysomnographs, gas analyzers, and sleep test devices. Reagents employed in respiratory diagnostics include buffers, control solutions, calibration solutions, nucleotides, enzymes such as DNA polymerases, primers, probes, dyes, and reactants for sample preparation. Assays, including the reverse transcriptase polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and rapid diagnostic tests (RDTs), are frequently utilized for the detection of antibodies or antigens related to respiratory pathogens. Software and services play a pivotal role in managing patient health records, data analysis, and facilitating connections between different healthcare entities. Software solutions and services, such as electronic health records (EHRs) and hospital information systems (HIS), offer streamlined data management and efficient diagnostic results communication. Services include professional consultation, device implementation, user training, and regular diagnostics device maintenance.

End-User: Adoption of a diverse range of diagnostic tools in hospitals and clinics for identifying and monitoring respiratory ailments
Diagnostic laboratories form a critical component of the end-use landscape for respiratory diagnostics. These entities are consistently involved in testing and diagnosis of various respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, and pneumonia. With their highly advanced and complex set of testing equipment, diagnostic laboratories offer accurate and reliable results, serving as a key milestone in the patient's journey toward appropriate treatment and recovery. Hospitals, given their primary role in healthcare delivery, are equipped with state-of-the-art respiratory diagnostics tools for identifying respiratory diseases. Their usage extends from outpatient departments to intensive care units, bringing precise and timely diagnostics to the broadest set of patients. Research institutes play an indispensable role in the field of respiratory diagnostics. These institutions are vital in both evaluating the efficacy of existing diagnostic tools and developing the next generation of respiratory diagnostic solutions. They facilitate extensive research into diagnostic methods that can identify diseases at an earlier stage to increase the survival rate and minimize the impact on patient's quality of life.

Regional Insights:
The Americas pose a significant position in the global market for respiratory diagnostics. High incidences of respiratory diseases coupled with heightened awareness and proactive medical interventions contribute to the need for advanced respiratory diagnostics in the Americas. The availability of sophisticated healthcare infrastructure also facilitates the production of high-quality diagnostic equipment. The escalating demand for diagnostic services and the presence of rapidly developing healthcare infrastructure support the production of respiratory diagnostic devices in Asia. The prevalence of respiratory diseases and the expansion of key market players, both domestic and international,, have elevated market development in the region. Europe's market for respiratory diagnostics is heavily influenced by the high availability of innovative respiratory diagnostic tests and the presence of well-established healthcare systems. Regulatory guidelines laid down by the European Union also pave the way for stringent quality control during the production of respiratory diagnostic devices. Middle East & Africa also observes an increasing prevalence of respiratory diseases, creating a need for consistent availability of advanced diagnosis solutions. The production of respiratory diagnostic devices is limited in the region due to a lack of local manufacturers. However, various international companies are focusing on and have expanded their foothold in this region for respiratory diagnostic device manufacturing.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Respiratory Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Respiratory Diagnostics Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Respiratory Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaltis S.r.l., Altona Diagnostics GmbH, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., bioMérieux S.A., Bioneer Corporation, CerTest Biotec S.L., Daan Gene Co., Ltd., Diatech Pharmacogenetics srl, Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Hologic, Inc., Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Masimo Corporation, Medtronic PLC, Merck KGaA, ProAxsis by NetScientific PLC, Quest Diagnostics Incorporated, Quidel Corporation, Sansure Biotech Inc., SDI Diagnostics, Inc., Seegene Inc., Siemens Healthineers AG, Somnoware by ResMed Corp., Thermo Fisher Scientific Inc., Vitalograph Ltd., and ZeptoMetrix LLC.

Inquire Before Buying @

Market Segmentation & Coverage:

This research report categorizes the Respiratory Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Assays & Reagents, Instruments & Devices, and Software & Services. The Instruments & Devices commanded largest market share of 52.12% in 2022, followed by Assays & Reagents.

Based on Test Type, market is studied across Imaging Tests, Mechanical Tests, Molecular Diagnostic Tests, OSA Diagnostic Tests, and Traditional Diagnostic Tests. The Imaging Tests is further studied across Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, and X-Ray. The Mechanical Tests is further studied across Peak Flow Test, Pulmonary Function Tests, and Spirometry. The Molecular Diagnostic Tests is further studied across DNA Sequencing & Next-Generation Sequencing, In Situ Hybridization, Microarrays, Nucleic Acid Amplification Test, and PCR. The Traditional Diagnostic Tests is further studied across Biochemical Tests, Immunodiagnostics, and Microscopy. The Molecular Diagnostic Tests commanded largest market share of 29.21% in 2022, followed by Imaging Tests.

Based on Indication, market is studied across Asthma, Chronic Obstructive Pulmonary Disease, Lung Cancer, Pneumonia, and Tuberculosis. The Chronic Obstructive Pulmonary Disease commanded largest market share of 25.17% in 2022, followed by Tuberculosis.

Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes. The Diagnostic Laboratories commanded largest market share of 43.53% in 2022, followed by Hospitals & Clinics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 38.14% in 2022, followed by Americas.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Respiratory Diagnostics Market, by Product
7. Respiratory Diagnostics Market, by Test Type
8. Respiratory Diagnostics Market, by Indication
9. Respiratory Diagnostics Market, by End-User
10. Americas Respiratory Diagnostics Market
11. Asia-Pacific Respiratory Diagnostics Market
12. Europe, Middle East & Africa Respiratory Diagnostics Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Respiratory Diagnostics Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Respiratory Diagnostics Market?
3. What is the competitive strategic window for opportunities in the Respiratory Diagnostics Market?
4. What are the technology trends and regulatory frameworks in the Respiratory Diagnostics Market?
5. What is the market share of the leading vendors in the Respiratory Diagnostics Market?
6. What modes and strategic moves are considered suitable for entering the Respiratory Diagnostics Market?

Read More @

Mr. Ketan Rohom
+1 530-264-8485

Powered by EIN Presswire
Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release